We’re discovering and developing first-in-class therapeutics for synaptopathies by applying novel chemical strategies to design molecules that safely upregulate genes crucial to learning and memory.
Our targeted approach to enhancing synaptic integrity, backed by a robust translational strategy, has potential across multiple synaptopathies, including Alzheimer’s, Parkinson’s, frontotemporal dementia, schizophrenia and major depressive disorder, all of which are characterized by impaired neuronal and synaptic function.
We’re driven by a vision of significantly and durably improving the quality of life for patients and their caregivers. Many of us have friends and relatives who have been diagnosed with devastating synaptopathies. Our mission is to help them, and millions like them, live more independent and satisfying lives.
Our leadership team has decades of experience in drug discovery, translational strategy, corporate development and commercialization. Collectively, we have been instrumental in bringing 15 drugs to the market and advancing more than 50 molecules into clinical development. Together, we have more than 100 years of experience in neuroscience.